Key result
Among 52 FDA-approved small-molecule kinase inhibitors, 73% (38 of 52) have reported treatment-related cardiotoxicity, most commonly QT prolongation and hypertension.
Why the study?
Small-molecule kinase inhibitor-induced cardiotoxicity represents a life-threatening risk in cancer treatment requiring comprehensive evaluation across approved agents.
What is the incidence and spectrum of cardiotoxicity associated with FDA-approved small-molecule kinase inhibitors?
What is the incidence and spectrum of cardiotoxicity associated with FDA-approved small-molecule kinase inhibitors?
A large proportion (73%) of FDA-approved small-molecule kinase inhibitors are associated with significant cardiotoxicity, highlighting the critical need for proactive cardiac monitoring during targeted cancer therapy.
Answers are grounded in this paper and cite their sources.
High cardiotoxicity rates with SMKIs warrant close monitoring; leaves open targeted prevention trials.
Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA. With the numerous clinical trials and a heavy focus on drug safety, SMKI-induced cardiotoxicity, which is a life-threatening risk, has greatly attracted the attention of researchers. In this review, the SMKIs with cardiotoxicity incidence were described exhaustively. The data were collected from 42 clinical trials, 25 FDA-published documents, seven meta-analysis/systematic reviews, three case reports and more than 50 other types of articles. To date, 73% (38 of 52) of SMKIs have reported treatment-related cardiotoxicity. Among the 38 SMKIs with known cardiotoxicity, the rates of incidence of cardiac adverse events were QT prolongation: 47% (18 of 38), hypertension: 40% (15 of 38), left ventricular dysfunction: 34% (13 of 38), arrhythmia: 34% (13 of 38), heart failure: 26% (10 of 38) and ischemia or myocardial infarction: 29% (11 of 38). In the development process of novel SMKIs, more attention should be paid to balancing the treatment efficacy and the risk of cardiotoxicity. In preclinical drug studies, producing an accurate and reliable cardiotoxicity evaluation model is of key importance. To avoid the clinical potential cardiotoxicity risk and discontinuation of a highly effective drug, patients treated with SMKIs should be proactively monitored on the basis of a global standard. Moreover, the underlying mechanisms of SMKI-induced cardiotoxicity need to be further studied to develop new therapies for SMKI-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2020) conducted a review in Cancer. Small-molecule kinase inhibitors was evaluated on Incidence of treatment-related cardiotoxicity. Among 52 FDA-approved small-molecule kinase inhibitors, 73% (38 of 52) have reported treatment-related cardiotoxicity, most commonly QT prolongation and hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: